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Abstract: Targeted tumor therapy can provide the basis for the inhibition of tumor growth. However,
a number of toxin-based therapeutics lack efficacy because of insufficient endosomal escape after
being internalized by endocytosis. To address this problem, the potential of glycosylated triterpenoids,
such as SO1861, as endosomal escape enhancers (EEE) for superparamagnetic iron oxide nanoparticle
(SPION)-based toxin therapy was investigated. Herein, two different SPION-based particle systems
were synthesized, each selectively functionalized with either the targeted toxin, dianthin-epidermal
growth factor (DiaEGF), or the EEE, SO1861. After applying both particle systems in vitro, an almost
2000-fold enhancement in tumor cell cytotoxicity compared to the monotherapy with SPION-DiaEGF
and a 6.7-fold gain in specificity was observed. Thus, the required dose of the formulation was
appreciably reduced, and the therapeutic window widened.
Keywords: surface modification; functionalization; drug delivery; saponin; SO1861; EGF; targeted
toxin; endosomal escape
1. Introduction
Colorectal cancer is one of the leading causes of cancer-related deaths worldwide [1].
To date surgery is the conventional treatment, which is often accompanied by radiation- or
chemotherapy. However, these supportive therapy methods lack specificity in the treatment
of tumorous tissues, leading to severe toxic side effects and limited possible treatment doses.
To overcome these drawbacks, the concept of targeted tumor therapy, which focuses on the
development of novel adjuvant cancer treatments to solely target cancerous cells, stands
out as a promising technology. For this purpose, specific targeted delivery vehicles, such as
nanoparticle- or protein-based systems, have been designed [2,3]. The latter encompasses
so-called targeted toxins—a group of therapeutics which comprise a toxic protein with
enzymatic activity and a targeting moiety, addressing specific markers on the cellular
surface of cancer cells. In particular, the epidermal growth factor receptor (EGFR) is known
to be overexpressed in a variety of human cancer cell lines including pancreatic, breast, and
colorectal cancers, and thus is an ideal marker for targeted tumor therapy [4,5]. Moreover,
selectively addressing EGFR yields an optimized cellular internalization, which is crucial
for improving the treatment efficacy and reducing the needed treatment dosage [6–8].
Nevertheless, the majority of macromolecular anti-tumor substances are internalized via
receptor-mediated endocytosis [9,10], resulting in a pH-dependent degradation of the deliv-
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ered therapeutics within the up-taking endosomes, and thus in a reduced effectiveness [11].
Consequently, a major bottleneck is the limited entry of the drug into the cytosol, as most
of the delivered antitumor therapeutics are cytosolically active (macro-)molecules [12,13].
Thus, commonly high serum levels of the therapeutics are employed to overcome insuffi-
cient cytosolic entry and to ensure sufficient efficacy, resulting in severe side effects such as
immunogenicity and vascular leak syndrome [14,15]. In order to circumvent this drawback,
several systems have been studied to date as efficacy enhancers including the attenuation
of the membrane integrity of endosomal membranes, disruption of endosomes, or uti-
lization of cell penetrating peptides [16–19]. Notably, certain plant secondary metabolites
(glycosylated triterpenoids) were shown to tremendously facilitate the endosomal escape,
due to a destabilizing effect on the endosomal membrane while the plasma membrane
remains unaffected, finally resulting in substantially improved anti-tumor activity of spe-
cific protein-based targeted toxins [20–22]. However, the specific mechanism of interaction
between glycosylated triterpenoids and cellular membranes remains unclear, although sev-
eral studies have been conducted to date [13,23]. In particular, the glycosylated triterpenoid
SO1861, extracted from Saponaria officinalis L., was reported to exhibit this property when
concomitantly administered with dianthin (Dia), a plant toxin from Dianthus caryophyllus
L. [12,24,25]. Dia belongs to the class of ribosome-inactivating proteins (RIP) that cut
off a specific adenine residue from ribosomal RNA, which finally results in the arrest of
protein synthesis and apoptosis. However, for in vivo applications it needs to be taken into
account that glycosylated triterpenoids are rapidly and unspecifically distributed inside
an organism with disparate kinetics than Dia [26]. Moreover, the components, SO1861
and Dia, need to be delivered via two different routes, which limits the compatibility
of the approach as a versatile platform [27]. Thus, for the realization of an augmented
efficacy via enhanced endosomal escape mechanisms, the development of formulations for
multi-component systems is of essential importance in order to synchronize the individual
pharmacokinetics.
A promising approach to face these challenges is the use of nanomedicine, which
focuses on the design of novel formulations for site-specific therapies. Superparamagnetic
iron oxide nanoparticles (SPIONs) are highly promising for many nanomedical applications,
as they have been shown to serve as a nanoscale carrier platform for various therapeutic
agents because of their unique magnetic properties and their biocompatibility [28–32]. Fur-
thermore, a suitable surface functionalization enables the defined coordination of different
types of drugs and a tuning of the biochemical properties. Nonetheless, there are several
problems of many common functionalization strategies, in particular the heterogeneity
of the final product, the possibility of cross-linkage between particles, and the formation
of oligomers at the particle surface. Furthermore, to render SPIONs viable for clinical
translation, it is necessary to assure high efficacies to reduce the probability of side effects.
To the best of our knowledge, no studies have yet been performed that examine the effect
of glycosylated triterpenoid based endosomal escape enhancers (EEE) on the toxicity of
RIP-modified nanoparticles on cancer cells.
Herein, the suitability of SO1861 to act as an EEE for SPION-based Dia delivery
systems was investigated. Therefore, we present a defined route using strain-promoted
azide–alkyne cycloaddition “click-chemistry” for selectively functionalizing SPIONs with
Dia as well as EGFR-targeted dianthin (Dianthin-EGF; DiaEGF). The obtained particle
systems were characterized by several methods, such as transmission electron microscopy
(TEM), thermogravimetric analysis (TGA), and dynamic light scattering (DLS). The efficacy
of Dia and DiaEGF after immobilization on the SPION surface was tested in vitro on
colorectal cancer cells. Furthermore, the ability of SO1861 to enhance the efficacy of RIP-
functionalized SPIONs was investigated in two combinatorial approaches (Figure 1 and
Figure S1). At first, SO1861 was added as a bare solution to the particle systems. Secondly,
SO1861 was conjugated separately on SPIONs and added as a particle mixture together
with RIP-functionalized SPIONs to the cells in order to unify the pharmacokinetics of the
RIPs and SO1861.
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Diego, CA, USA). 1-[Bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 
3-oxide hexafluorophosphate (HATU) was purchased from Santa Cruz Biotechnology, 
Inc. (Dallas, Texas, USA) Hydrogen peroxide solution (30%, A. C. S. reagent) was supplied 
by Merck KGaA (Darmstadt, Germany). Ethanol (HPLC grade) and dimethyl sulfoxide 
(DMSO, HPLC grade) were bought from Fisher Scientific GmbH. 
Unless otherwise specified, de-ionized water was used. However, the HEPES buffer 
was prepared as a 10 mM solution using Milli-Q water. The pH was adjusted to 7.4 by 
1 M NaOH solution. 
2.2. SPION Synthesis and APTES Modification 
The SPIONs were synthesized and modified with APTES (SPION@APTES) in a one-
step co-precipitation method. In a typical synthetic procedure, 0.75 g of FeCl3∙6H2O and 
0.375 g of FeCl2∙4H2O were dissolved in 50 mL de-ionized water (dH2O) in a 100 ml three-
necked round bottom flask. The solution was refluxed at 80 °C and stirred for 10 min un-
der nitrogen atmosphere. Then, 10 mL of NH4OH (28–30% aqueous solution) was injected 
dropwise, via a syringe to the solution. After one hour, 15 mL of EtOH, followed by a 
previously prepared solution of 2 mL of APTES in 25 mL EtOH, was added to the reaction 
mixture and stirred for further 3 h at 80 °C. Prior to the purification, the suspension was 
allowed to cool to room temperature (RT). Then, as-synthesized nanoparticles were re-
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2. Materials and Methods
2.1. Chemicals and Reagents
Acetone (≥99.9%), (3-aminopropyl)triethoxysilane (APTES, 99%), (1R, 8S, 9s)-bicyclo[6.1.0]
non-4-yn-9-yl-methyl-N-succinimidyl carbonate (BC -NHS), dimethylformamide (DMF,
9.8%, A. C. S. reagent), iron(II) chlorid tetrahydrate (FeCl2·4H2O, ≥99%), iron(III)
chloride hexahydrate (FeCl3·6H2O, ≥99%), 4-(2-hydroxyeth l)-1-piperazineethanesulfonic
acid (HEPES, ≥99.5%), hydrochloric acid (37%), sodium hydroxide (NaOH, ≥97%), 3-
(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazoliumbromide (MTT, 98%), ammonium hy-
droxide solution (NH4OH, 28.0–30.0%), and triethylamine (TEA, ≥99.5%) were obtained
from Sigma-Aldrich Chemie GmbH (Taufkirchen, Germany). Azido-PEG12-NHS ester
(N3-PEG12-NHS, >95%) was acquired from Conju-Probe LLC (San Diego, CA, USA).
1-[Bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3-oxide hexafluo-
rophosphate (HATU) was purchased from Santa Cruz Biotechnology, Inc. (Dallas, Texas,
USA) Hydrogen peroxide solution (30%, A. C. S. reagent) was supplied by Merck KGaA
(Darmstadt, Germany). Ethanol (HPLC grade) and dimethyl sulfoxide (DMSO, HPLC
grade) were bought from Fisher Scientific GmbH (Munich, Germany).
Unless otherwise specified, de-ionized water was used. However, the HEPES buffer
was prepared as a 10 mM solution using Milli-Q water. The pH was adjusted to 7.4 by 1 M
NaOH solution.
2.2. SPION Synthesis and APTES Modification
The SPIONs were synthesized and modified with APTES (SPION@APTES) in a one-
step co-precipitation method. In a typical synthetic procedure, 0.75 g of FeCl3·6H2O and
0.375 g of FeCl2·4H2O were dissolved in 50 mL de-ionized water (dH2O) in a 100 mL
three-necked round bottom flask. The solution was refluxed at 80 ◦C and stirred for 10 min
under nitrogen atmosphere. Then, 10 mL of NH4OH (28–30% aqueous solution) was
injected dropwise, via a syringe to the solution. After one hour, 15 mL of EtOH, followed
by a previously prepared solution of 2 mL of APTES in 25 mL EtOH, was added to the
reaction mixture and stirred for further 3 h at 80 ◦C. Prior to the purification, the suspension
was allowed to cool to room temperature (RT). Then, as-synthesized nanoparticles were
retrieved from the mixture by the addition of acetone (5:1 v/v acetone/supernatant) as
precipitant, followed by centrifugation for 10 min at 8500 rpm, resuspended in 20 mL dH2O,
and dialyzed against 2 L dH2O for 24 h. The resulting magnetic nanoparticle concentration
of 26.67 mg/mL was determined gravimetrically.
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2.3. BCN Modification
To implement selective binding sites between the RIPs and the particle surface,
SPION@APTES was first modified with BCN-NHS (SPION-BCN) according to Asadian-
Birjand et al. [33], with slight modifications. 376 µL of the aqueous SPION@APTES sus-
pension (10 mg SPIONs) and 50 µL of TEA were diluted with 20 mL DMF. Thereafter, a
twofold molar excess of BCN-NHS (1.02 mg), with respect to the peripheral amine moieties
of SPION@APTES, was added and the reaction was carried out for 18 h at RT on a shaking
device. The molar quantity of the grafted amine moieties per gSPIONs was calculated from
TGA measurements according to Equation (2) (see Section 2.11). Afterwards, the particles
were centrifuged for 10 min at 8500 rpm and the supernatant was replaced with HEPES
buffer for three times.
2.4. Expression and Purification of Dia and DiaEGF
Purification and expression of Hisdianthin-30, hereafter simply referred to as Dia, and
DiaEGF was performed as reported previously [34,35]. Briefly, plasmids (His6-tagged-
dianthin-30-pET11d and His6-tagged-dianthin-EGF-pET11d) were transformed into Es-
cherichia coli NiCo21(DE3) competent cells (Novagen, San Diego, CA, USA). To induce the
expression of the RIPs, isopropyl β-D-1-thiogalactopyranoside (IPTG) was added at a final
concentration of 1 mM. After 3 h of incubation at 37 ◦C and 120 rpm, bacterial suspensions
were lysed by sonication with an ultrasound device (Branson Sonifier 250, G. Heine-
mann, Schwäbisch Gmünd, Germany). Purification of the released His6-tagged-toxins was
achieved by nickel nitrilotriacetic acid chromatography (Ni-NTA Agarose; Qiagen, Hilden,
Germany) followed by chitin column affinity chromatography, which served to remove
bacterial proteins with binding activity for Ni-NTA agarose. Afterwards, the purity of
the recombinant proteins was analyzed by sodium dodecyl sulfate-poly acrylamide gel
electrophoresis (SDS-PAGE, 12% [w/v] gel) and the concentration was determined by a
bicinchoninic acid (BCA) assay (Pierce, Rockford, IL, USA).
2.5. Modification of Dia and DiaEGF
To bind the RIPs specifically to the particles, and thus prevent crosslinking reactions,
the toxins were first provided with the azide click ligand NHS-PEG12-N3 for a copper
free strain-promoted alkyne-azide cycloaddition. Therefore, and to study the conjugation
efficiency of the NHS-PEG12-N3 linker to the toxins, three different molar ratios (1.5, 3.0,
20 mollinker/moltoxin) were employed. 0.3 mg of the respective RIP was mixed with the
correspondent amount of the PEG linker and incubated for 3 h at 20 ◦C and 800 rpm in
Dulbecco’s phosphate-buffered saline buffer. The conjugates were washed three times with
the same buffer by means of Amicon centrifugal filter devices (10 kDa; Merck Millipore,
Burlington, MA, USA). Successful conjugation was confirmed by matrix-assisted laser
desorption ionization time of flight mass spectrometry (MALDI-TOF-MS), which was
conducted on an Ultraflex-III TOF/TOF instrument (Bruker Daltonics, Billerica, MA, USA)
equipped with a 200 Hz N2-laser with 337 nm wavelength (pulse energy of 150 µJ) and
3 ns pulse width, and operated in the positive linear mode.
2.6. Determination of Enzymatic Activity
N-glycosidase activity of RIPs was determined by an adenine release assay which is
based on the cleavage and release of adenine residues from herring sperm DNA [25]. First,
an adenine standard curve was prepared by determining the absorbance at 260 nm for
different adenine concentrations (10, 20, 40, 80, 160, and 320 pmol/µL). A NanoDrop ND-
1000 spectrophotometer (PEQLAB Biotechnologie GmbH, Erlangen, Germany) was used
to measure the absorbance. Afterwards, a herring sperm DNA stock solution (5 µg/µL;
Invitrogen, Carlsbad, CA, USA) was prepared using a 50 mM sodium acetate buffer (pH
4, 100 mM KCl) and preheated at 50 ◦C for 10 min. Then, 20 µL of the stock solution was
added to 30 pmol of the unmodified and modified RIPs and diluted to a total volume of
50 µL by addition of acetate buffer. The reaction was then carried out at 50 ◦C for 1 h under
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continuous shaking. Subsequently, the released adenine was separated by centrifugation
with filter membranes (3000 MWCO; Merck Millipore, Burlington, MA, USA) for 45 min at
4 ◦C and 5000× g. Finally, the absorbance of the flow-through was measured at 260 nm.
Quantification of adenine release was calculated by the use of the adenine calibration curve.
2.7. RIP Conjugation to SPIONs (SPION-Dia, SPION-DiaEGF)
0.75 mg of the respective modified RIP (Dia or DiaEGF) was added to 5 mg SPION-
BCN in 15 mL HEPES buffer and incubated at RT for 20 h on a shaking device. The
subsequent purification was carried out by repeated magnetic precipitation of the particles,
exchanging the supernatant for three times. In addition, a negative control ensured that un-
conjugated RIPs were efficiently removed during subsequent washing and dispersing steps.
For this purpose, 0.75 mg of DiaEGF was added to 5 mg SPION@APTES without prior
modification by BCN-NHS and N3-PEG12-NHS, respectively. Incubation and purification
were carried out under same conditions as mentioned in the section of BCN modification.
2.8. SO1861 Isolation
SO1861 was isolated from Saponaria officinalis L. caryophyllacea by methanol extraction
of the powdered plant roots, acetone precipitation, and high performance liquid chromatog-
raphy, as reported elsewhere [36]. Purity and identity of SO1861 were analyzed via LC/MS
with an Agilent 6210 TOF LC/MS system.
2.9. Synthesis of SPION-SO1861
Coupling of SO1861 to the SPION surface (SPION-SO1861) was achieved using HATU
as a zero-length crosslinker. Therefore, HATU and SO1861 were each first dissolved in
DMSO with a concentration of 1 mg/mL. Then, 0.83 mL of HATU was added to 0.812
mL SO1861 and reacted for 20 min at RT and 800 rpm. Afterwards, activated SO1861 was
added to 1 mg of SPION@APTES in 3 mL DMSO. The reaction was incubated for 18 h at
RT and subsequently washed three times by centrifugation for 12 min at 8500 rpm with
HEPES buffer. Analogous to the protein conjugation, non-activated SO1861 served as
control to validate the purification efficiency. Thus, the reaction was repeated without prior
activation of SO1861 by HATU. The experimental setup, as well as the washing procedure
was carried out as described for the SPION-APTES modification.
2.10. Cell Culture
HCT-116 (colorectal carcinoma) and MDA-MB-453 (breast carcinoma) were cultured
in Roti®-CELL McCoy’s 5A and Leibovitz’s L-15 medium, respectively, supplemented with
10% fetal bovine serum (BioChromKG, Berlin, Germany) and 1% penicillin/streptomycin
(Gibco/Invitrogen, Karlsruhe, Germany). HCT-116 cells overexpress EGFR on their cellular
surface and were grown in humidified incubators at 5% CO2 and 37 ◦C [37]. In contrast,
MDA-MB-435 cells do not express EGFR and thus served as off-target cells, which were
cultivated at 37 ◦C without CO2 [38].
Cytotoxicity studies were essentially carried out as described in past publications using
an MTT assay [35]. Cells were seeded (3000 cells/well for HCT-116 and 30,000 cells/well
for MDA-MB-453) on a 96-well plate in 100 µL medium and grown for 24 h. 80 µL of
media and 20 µL HEPES buffer containing different iron concentrations (up to 2 mM Fe3+
final concentration) were added. Controls were provided with only 20 µL HEPES buffer.
Regarding the combinatorial approach with free SO1861, cells were first incubated with
0.5 µg/mL SO1861 in 80 µL media for 15 min at RT and subsequently treated with SPIONs,
suspended in 20 µL HEPES buffer. For the second combinatorial approach with conjugated
SO1861, SPION-RIPs and SPION-SO1861 were mixed together and applied in 20 µL HEPES
buffer at the same time. All cytotoxicity studies were carried out for 48 h. Afterwards, the
media was aspirated and 200 µL of fresh media and 30 µL of a 5 mg/mL MTT solution were
added and incubated for further 2 h at 37 ◦C. Thereafter, the supernatant was removed
again, and formazan crystals were dissolved with 50 µL DMSO for 15 min on a shaker.
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Prior to the measurement, remaining particles were removed by placing a flat magnet
under the plate and transferring the supernatant to another 96-well plate. The absorbance
was measured at 570 nm (reference at 630 nm) by the SpectraMax 340PC Absorbance
Microplate Reader (Molecular Devices, Sunnyvale, CA, USA). The relative cell viability
related to control samples was calculated and as a result, the characteristic half-maximum
inhibitory concentration (IC50) was determined as a quantitative measure. Furthermore,
the enhancement factor (EF) for both combinatorial approaches was determined using the
IC50-value of SPION-RIP (IC50,-SO1861) and the IC50-value after additional application of





2.11. Characterization of SPIONs
The morphology and size of the obtained SPIONs were studied by transmission
electron microscopy (TEM) using a Tecnai G2 F20 TMP from FEI at 200 kV. The particles
were deposited on a carbon film of a 3.05 mm woven copper net with 300 mesh from Plano
GmbH. Particle sizes were determined by measuring 50 nanoparticles, using the ImageJ
software (Version 1.42q). Hydrodynamic diameter and size distribution measurements
were performed on a Zetasizer Nano-ZS from Malvern Instruments (Kassel, Germany) by
dynamic light scattering (DLS). All samples were characterized as aqueous suspensions
for three times with a 173◦ backscatter geometry at 25 ◦C. Zeta potentials were evaluated
by the same device using a capillary zeta cuvette (DTS1070C, Malvern Panalytical Ltd).
Qualitative information on the molecules linked to the particle surface was obtained by
FTIR spectrometry. Therefore, dried samples were analyzed with a Bruker Vertex 70,
equipped with an attenuated total reflectance (ATR) cell. Thermogravimetric analysis
(TGA) was carried out using a TGA/DSC 1 STARe system and a gas controller 4C200
STARe system from Mettler Toledo. 10 mg of the dried sample was heated at a rate of
10 ◦C/min under an oxygen atmosphere. Based on the recorded thermograms, the molar




given in molligand ∗ g−1SPION (2)
with ∆mmod and ∆munmod being the mass loss of modified and unmodified SPIONs in
percent, respectively, and Mligand being the molecular mass of the ligand. The number of
molecules grafted on the SPION surface per square nanometer (referred as grafting density




given in molecules ∗ nm−2 (3)
where NA is the Avogadro number and SA the specific surface area in m2 gSPION−1. SA
was determined via nitrogen sorption measurements on the unmodified nanoparticles
using the multipoint Brunauer, Emmett, and Teller (BET) surface analyzer ASAP 2460 from
Micromeritics (Norcross, GA, USA). Therefore, the particles were first degassed under a
vacuum for 2 h at 120 ◦C.
T1 and T2 relaxation times and relaxivities were determined on a TD-NMR analyzer
at 0.94 T (minispec nq40 NMR analyzer, Bruker, Billerica, MA, USA). The values were
measured at 40 ◦C in water at different iron concentrations.
3. Results and Discussion
3.1. Expression, Purification and Modification of Dia and DiaEGF
After recombinant expression in bacteria, Dia and DiaEGF were purified by Ni-NTA
and chitin column affinity chromatography. Comprehensive analyses of the expression and
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purification of Dia and DiaEGF were carried in our previous studies [24,34,40] and will not
be discussed in detail here. However, both RIPs, Dia and DiaEGF, appear as a single band
in the SDS-PAGE (Figure S2) at approximately 30 kDa and 36 kDa, respectively, and thus
no degradation products were observable. The obtained masses of Dia and DiaEGF were
confirmed via MALDI-TOF-MS measurements in positive linear mode (Figures S3 and S4).
For the processing of the final anti-tumor particle system, it is substantial to maintain a
high enzymatic activity of the RIPs and a functional EGF binding domain in DiaEGF. This
is accomplished by ensuring that RIPs are specifically bound to the SPION surface without
uncontrolled crosslinking reactions. To this end, Dia and DiaEGF were first decorated with
the heterobifunctional NHS-PEG12-N3 linker by amide bond formation between the NHS
group of the linker and the lysine moieties of the proteins. To enable a precise adjustment
of the conjugation density, three different feed ratios of linker to RIP were explored and
analyzed by MALDI-TOF-MS (Figures S3 and S4).
The derived conjugation efficiency is shown in Figure 2A. Accordingly, the maximum
number of conjugable linker molecules is restricted by the amount and accessibility of
lysine groups present in the tertiary structure of the RIPs. A 20-times molar excess of linker
to RIP resulted in the attachment of six and four linker molecules per Dia and DiaEGF,
respectively. It is worthwhile to note that even though Dia contains 19 and DiaEGF 21
lysine moieties [25,40], only a small fraction of the linker molecules could be attached,
showing that their accessibility is of utmost importance. A slightly larger number of
linkers were conjugated to Dia than to DiaEGF, which can be ascribed to the occupancy
of potentially accessible lysine residues by the fusion of EGF to Dia. To ensure that the
anti-tumoral efficiency of the conjugates was not decisively declining, the N-glycosidase
activity of the RIP domain was determined using an adenine release assay (Figure 2B).
Accordingly, 203.4 pmol adenine/pmol toxin/h (100%) was released by ligand-free Dia,
compared to 113.0 pmol adenine/pmol toxin/h in case of DiaEGF. Thus, 44.4% loss in
catalytic activity occurred, which is commonly observed when RIPs are expressed as
targeted toxins [25,34,40,41]. In contrast, conjugation of NHS-PEG12-N3 to Dia or DiaEGF
only caused a moderate decrease in the enzymatic activity of approximately 25 and 9%,
respectively. Interestingly, no significant differences were observed when the number of
conjugated linkers was increased, indicating that lysines located close to the active center
are always included in the conjugation reaction or do not affect the activity when conjugated
with a linker that is rather small, compared to EGF. Nevertheless, all conjugates were still
highly active and thus could be utilized for further processing. In order to facilitate the
reaction of RIPs towards the SPION surface, RIP conjugates with the largest number of
bound linkers were used for subsequent particle functionalization. Since SPIONs were
functionalized with an excess of BCN compared to the subsequently added amount of
RIP conjugates, the potential number of bound RIPs should not be limited even if one RIP
reacts with multiple BCN linker molecules on the particle surface.
3.2. Characterization of Synthesized and RIP-Functionalized SPIONs
SPIONs were utilized as delivery platforms for Dia and DiaEGF, as well as for SO1861.
For an understanding of the precise effect of the RIPs and SO1861 after their conjugation
to the SPIONs, it is indispensable to thoroughly characterize the as synthesized and
subsequently functionalized particle systems. The recorded X-ray diffraction (XRD) pattern
of the as synthesized SPIONs is depicted in the Figure S5. Applying the Debye–Scherrer
equation to the highest intensity reflection at 35.5◦ with a full width at half maximum of
0.7◦, KS of 0.9 and wavelength λ of 0.154 nm, a crystallite size of 12.8 nm was determined.
This is in good agreement with the mean particle size of 11.9 ± 2.5 nm analyzed by
TEM (Figure 3A), considering the measurement uncertainties. Furthermore, a relatively
uniform spherical morphology of the SPIONs was obtained. As expected, the particle sizes
measured by DLS (Figure 3B) were larger than the ones determined by TEM, since DLS
takes into account not only the particle core, but also the APTES coating, as well as the
hydration shell. A hydrodynamic diameter of 75 nm for SPION@APTES suggests that
smaller SPION aggregates were silanized rather than individual particles. Subsequent
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conjugation of BCN and Dia or DiaEGF resulted in a further increase in hydrodynamic size
by 6, 18, and 27 nm, respectively, indicating the additional presence of these larger ligands
at the SPION surface.
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In addition, the zeta potential of the individual precursors and the particle systems
after each functionalization step was measured (Figure 4A). After APTES modification,
SPION@APTES shows a highly positive zeta potential. Successive functionalization leads
to a severe shielding of surface charges in addition to higher particle volumes. Both
result in a declining electrophoretic mobility and hence a decrease of the zeta potential.
Nevertheless, the particles are not subjected to a significant tendency to agglomerate, as
shown in the DLS curves—presumably due to steric stabilization.
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Figure 4. (A) Zeta potential measurements and (B) obtained thermograms after each functionalization step.
To determine the amount of successfully conjugated ligand, thermal analyses were
carried out (Figure 4B). The thermogram of pristine SPIONs shows a loss of 1.2 wt%
within the ramp to 105 ◦C, as a result of water desorption. Upon further heating, a slight
increase in mass by 0.6 wt% was noted, which is related to the oxidation of magnetite to
maghemite [42], followed by a continuous decline of 1.6 wt%, due to decomposition of
surface-bound organic compounds. In contrast, SPION@APTES exhibit a total mass loss
of approximately 3.1 wt%. With SA determined as 83 m2/gSPION, the grafting density of
APTES can be calculated to 1.3 moleculesAPTES/nm2 using Equations (2) and (3). According
to our previous study [39], this can be correlated with the formation of a homogenous
monolayer, which is important for achieving the highest possible grafting density in
addition to an evenly distributed surface coverage. Immobilization of Dia or DiaEGF leads
to a greater mass loss of 13.9 and 18.8 wt%, respectively. The larger value for DiaEGF can
mainly be attributed to its larger molecular mass (36,182 Da) compared to Dia (29,666 Da).
Since FTIR spectroscopy did not reveal significant differences that can be used to verify
the linkage between RIPs and SPIONs (Supplementary Information, Figure S6), a negative
control was applied without utilizing the click ligands required for a covalent conjugation
between RIP and SPION. The recorded total mass loss accounts for only 3.6 wt%, which
ensures that unreacted RIPs are efficiently removed in the standard purification steps of
the functionalization procedure, and thus, the greater mass losses obtained for SPION-Dia
and SPION-DiaEGF can solely be attributed to chemisorbed RIPs.
3.3. Synthesis of SPION-SO1861
SO1861 was separately coordinated to SPION@APTES as a supplementary particle
system. The successful binding was confirmed by FTIR and zeta potential measurements,
as shown in Figure 5. The FTIR spectra (Figure 5A) of SPION@APTES and SPION-SO1861
show strong absorptions attributable to the Fe–O bonds at 535 cm−1. Furthermore, a
small peak at 1650 cm−1 is apparent, which can be attributed to the bending mode of
free amino (–NH2) groups. Because of the formation of amide bonds associated with the
carbonyl (–C=O) stretching vibration at 1654 cm−1, the peak becomes significantly stronger
for SPION-SO1861 [43]. In addition, the appearance of a new broad band at 3390 cm−1
in the spectrum of SPION-SO1861 can be ascribed to hydroxyl (–O–H) groups present
in the sugar moieties of SO1861, which indicates the presence of SO1861 on the particle
surface. The strong CO2 absorption bands at 2000 and 2150 cm−1 in the spectrum of free
SO1861 result from system-related measurement interferences and are thus not relevant.
As a result of SO1861 binding to the amino-terminated particle surface, the hydrodynamic
diameter of SPION@APTES increased slightly from 75 nm (Figure 3B) to 84 nm (Figure
S7). Furthermore, a change in the surface properties was also registered by analysis of the
electrophoretic mobility (Figure 5B). Accordingly, the zeta potential significantly shifted
from +36.2 mV to −17.1 mV, due to the binding of SO1861. In contrast, the zeta potential
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remained highly positive in the control experiment in which SPION@APTES was mixed
with bare SO1861. In the control experiment, no chemical reaction was expected to occur
between the SPION@APTES and SO1861, as the carboxylic acid group of SO1861 was not
activated by HATU. In summary, both the FTIR and zeta potential measurements strongly
indicate a successful conjugation of SO1861 to SPION@APTES.
Figure 5. (A) FTIR-spectra and (B) zeta potential measurements before and after functionalization
with SO1861. In the control experiment SPION@APTES and SO1861 were mixed together without
the addition of HATU.
3.4. In Vitro Cytotoxicity Studies
As shown above, the enzymatic activity of Dia and DiaEGF was either affected by
fusion of EGF to Dia or by attaching linker molecules to the RIPs. However, control
experiments of free Dia-PEG12-N3 and DiaEGF-PEG12-N3 conjugate (Figure S8) on the
target cells HCT-116 revealed that the RIP conjugates are still highly efficacious when
administered to the cells. Thus, in order to finally evaluate the functionality of Dia and
DiaEGF after their binding to SPION, the cytotoxicity and thus tumor cell therapeutic
potential of the complete particle systems was investigated in detail. Furthermore, the
influence of SPION@APTES and SPION-BCN on the cells was evaluated to assure that the
toxic effects are solely related to the bound RIPs. As depicted in Figure 6A and Table 1,
both SPION@APTES and SPION-BCN reduced the cell viability of the target cells HCT-116
to only 65% in the examined concentration range. Hence, it was not possible to calculate
the specific concentration of particles at which the cell growth was inhibited by 50% (IC50).
However, particles functionalized with Dia or DiaEGF exhibited a severe dose-dependent
decrease in cell viability. Thus, IC50 values of 5.5 × 10−4 and 1.3 × 10−5 M Fe3+ were
recorded for SPION-Dia and SPION-DiaEGF, respectively. Since a reduced IC50 value and
thus a higher cytotoxicity can be related to a greater accumulation of particles within the
cells, the obtained data verifies that the EGF binding domain of DiaEGF remained intact
and was sterically not effectively hampered by the conjugation on the particle surface to
act as targeting moiety. Since the employed surface chemistry for the linkage of the RIPs
on the particle surface results in a covalent bond, non-specific leakage of Dia or DiaEGF
can be neglected. Consequently, having in mind that Dia is only active in the cytosol, it
can be assumed that more particles are internalized into the cells. The targeting effect of
EGF can be quantified as the ratio of the IC50 values of SPION-Dia to SPION-DiaEGF,
which was 42, meaning that the targeting moiety provides a 42-fold increase in efficacy.
The specificity of SPION-DiaEGF towards EGFR-overexpressing cells was successfully
validated by concomitantly applying the particles on the non-target cell line, MDA-MB-453
(Figure 6B). In contrast to the target cell line, HCT-116, the toxic profiles of SPION-Dia
and SPION-DiaEGF on the non-target cell line differ only slightly. The marginally higher
cytotoxicity of SPION-DiaEGF may be ascribed to the non-specificity of the internalization
process of non-target cells, resulting in broad variation of ingested particles in addition
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to a remaining level of low EGFR expression on the cellular membrane of MDA-MB-
453 [44]. Thus, the obtained data in Figure 6A,B suggest that internalization of SPION-Dia
in general is primarily achieved by unspecific mechanisms, such as pinocytosis, whereas
SPION-DiaEGF seems to be ingested via receptor-mediated endocytosis, which is further
supported by the observed enhancer effect of SO1861 (see below).
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Table 1. Corresponding half maximal inhibitory concentration (IC50) values and enhancement factor (EF) derived from
Figures 6 and 7 of the respective particle based anti-tumor systems. Since the IC50 was not reached for SPION@APTES and
SPION@BCN, specification of the EF was not possible for these particle systems. The targeting effect is defined as the ratio
of the IC50 values of the non-targeted compound (SPION-Dia) to the targeted compound (SPION-DiaEGF). The gain in
specificity is the ratio of the targeted EF to the non-targeted EF.
w/o SO1861/M +SO1861/M EF +SPION-SO1861/M EF
SPION@APTES >2 × 10−3 4.5 × 10−5 – 2.2 × 10−5 –
SPION-BCN >2 × 10−3 – – – –
SPION-Dia 5.5 × 10−4 2.6 × 10−8 21,000 2.0 × 10−6 270
SPION-DiaEGF 1.3 × 10−5 4.0 × 10−10 33,000 7.5 × 10−9 1800
Targeting Effect 42 65 – 267 –
Gain in
Specificity – – 1.6 – 6.7
The suitability of SO1861 to facilitate the endosomal escape and synergistically en-
hance the toxicity of RIP loaded SPION, was validated in two combinatorial approaches.
First, the self-cytotoxicity of SO1861 on HCT-116 was evaluated (Supplementary Informa-
tion, Figure S9). Accordingly, this compound presented no cytotoxicity up to 2 µg/mL.
N vertheless, a concentration of 0.5 µg/mL was considered as non-toxic for the combi-
natorial cytotoxicity experiments. RIP-loaded SPIONs in combination with free SO1861
(SPION-RIP+SO1861) were highly toxic in a synergistic fashion (Figure 7A). The resulting
IC50 values (Table 1) were interpolated to 2.6 × 10−8 M Fe3+ and 4.0 × 10−10 M Fe3+
considering SPION-Dia and SPION-DiaEGF, respectively, corresponding to a targeting
effect of EGF of 65, which is slightly better than in the absence of SO1861. Consequently, a
cytotoxicity enhancement factor (EF) of around 21,000- and 33,000-fold was achieved for
SPION-Dia and SPION-DiaEGF. It is known that glycosylated triterpenoids also enhance
the cytotoxicity of non-targeted RIPs as long as such RIPs reach the endosomes [45], which
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appears to be partially the case for SPION-Dia. It may be assumed that SO1861 is indepen-
dently cointernalized within vesicles that contain RIP-loaded SPIONs, and consequently
affects the intracellular trafficking and endosomal release of the nanoparticles. This entails
that the RIP degradation in the lysosomes is circumvented and thus a greater number of
active RIPs are reaching the cytosol to inactivate the ribosomes. As a consequence, the
cells enter apoptosis after an enhanced inhibition of the protein synthesis, whereupon
cell death occurs [46]. Furthermore, it was examined whether SO1861 maintained the
ability to augment the cytotoxicity of RIP-loaded SPIONs even after its binding on the par-
ticle surface of SPIONs (SPION-RIP+SPION-SO1861). Self-cytotoxicity of SPION-SO1861
(Supplementary Information, Figure S10) showed no significant toxic effects in the area
of interest regarding the toxic profiles of the mixed particle systems, based on equimolar
blends of SPION-SO1861 and SPION-Dia or SPION-DiaEGF (Figure 7B). As listed in Table
1, IC50 values of 2.0 × 10−6 M Fe3+ and 7.5 × 10−9 M Fe3+ were determined for SPION-Dia
and SPION-DiaEGF in combination with SPION-SO1861, which was less effective than for
SPION-RIP+SO1861. The targeting effect of EGF, however, was 267 indicating that SPION-
SO1861 more specifically acted on SPION-DiaEGF than free SO1861, presumably due to the
adjusted kinetics and uptake mechanisms. The IC50 values correspond to an enhancement
factor of about 270 and 1800, respectively. It is worthwhile to note that the derived IC50
values were normalized to the amount of RIP-loaded SPIONs present in the respective
mixed particle system. In comparison to SPION-RIP+SO1861, SPION-RIP+SPION-SO1861
shows a lower EF. Nevertheless, the cytotoxicity augmentation is still clearly present,
evidencing that SO1861 does not forfeit its EEE activity. More importantly, the gain in
specificity was higher for SPION-RIP+SPION-SO1861 than for SPION-RIP+SO1861, i.e., the
EF ratio for the targeted SPION-DiaEGF compared to the non-targeted SPION-Dia is much
greater (6.7 versus 1.6, Table 1), indicating a substantially increased therapeutic window for
SPION-RIP+SPION-SO1861 (a ratio of 1.0 corresponds to no widening of the therapeutic
window). In addition, it is also important to highlight the lack of a targeting moiety in
SPION-SO1861, leading to unspecific cell uptake. The fabrication of SPION-based targeted
SO1861 systems thus appears to be a promising approach to further increase the efficacy
and prevent off-target effects, which will be investigated in future experiments.
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Figure 7. Cytotoxicity studies of SPIONs after each functionalization step o EGFR-overexpressing HCT-116 cells (A) applied
in a combinatorial approach with 0.5 µg/mL free SO1861 and (B) with SPION-SO1861, respectively. Cell viability was
assessed after 48 h by MTT-assay and plotted as a function of the molar iron concentration. Each point represents the mean
± SD of at least 3 independent experiments, performed in quadruplicate. Corresponding IC50 and EF values are shown in
Table 1.
3.5. Relaxivity Measurements
Due to their unique magnetic properties, SPIONs can serve not only as drug de-
livery systems, but also as a diagnostic tool for the detection of cancer via magnetic
resonance imaging [47]. Such systems, unifying therapeutic and diagnostic approaches,
are referred to as theranostics. To evaluate the potential of the particle mixture of SPION-
Nanomaterials 2021, 11, 1057 13 of 16
DiaEGF+SPION-SO1861 to be used as a theranostic system, the longitudinal (T1) and
transverse (T2) relaxation times of protons around the SPIONs were measured. Moreover,
the respective relaxivities r1 and r2, which represent the ability of the SPIONs to alter T1
and T2, respectively, were determined through the linear fitting of 1/T1 or 1/T2 versus the
iron concentration (Figure 8). As depicted in Figure 8A,B, SPION@APTES are characterized
by a low r1 (9.2 mM−1·s−1) and a high r2 (115 mM−1·s−1) value. SPIONs predominantly
shorten T2 relaxation time and thus provide negative contrast in T2-weighted images. The
relaxivity ratio r2/r1 further helps to estimate the efficiency of potential T2-contrast agents.
Here, the ratio was calculated to be 12.5. In comparison, slightly lower relaxivites of r1 equal
to 8.1 mM−1·s−1 and r2 equal to 97 mM−1·s−1 and thus a ratio of 11.9 was obtained for the
mixture of SPION-DiaEGF+SPION-SO1861. Shortening of the relaxation times is, among
other reasons, highly related to the surface properties [48]. Hence, the low decrease can be
ascribed to a limited magnetic interaction of the SPIONs with the surrounding aqueous
medium due to an enhanced steric hindrance as a result of ligand attachment. Nevertheless,
the determined values are comparable to those of commercially available SPION-based
contrast agents, such as Feridex/Endorem (r1 = 27 mM−1·s−1, r2 = 152 mM−1·s−1, r2/r1
= 5.6) or Resovist (r1 = 20.6 mM−1·s−1, r2 = 86 mM−1·s−1, r2/r1 = 4.2; relaxivities of the
commercial contrast agents were measured at 0.47 T in water at 40 ◦C [49]). Hence, these
data demonstrate that the mixture of SPION-DiaEGF+SPION-SO1861 could potentially
serve as a theranostic system using magnetic resonance imaging, which illustrates the
advantage of SPIONs as a carrier system compared to other particles.
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SPIONs as  carrier system comp red to other particles. 
 
Figure 8. (A) T1 and (B) T2 relaxivity measurements of SPION@APTES and the SPION-DiaEGF+ 
SPION-SO1861 mixture. Values of relaxivites (r1 and r2) were determined via correlation between 
the relaxation rates and the corresponding iron concentrations from the slope of the resulting linear 
regression curve. 
4. Conclusion 
This study presented the potential impact of glycosylated triterpenoids on SPION-
based targeted tumor therapies. For this purpose, SPIONs were synthesized and selec-
tively functionalized with Dia or DiaEGF, by the use of strain-promoted copper-free click 
chemistry. Extensive characterization of the as-synthesized and -functionalized particle 
systems showed that the functionalization process resulted in defined SPION-based anti-
tumor cell systems without unspecific interparticle or intermolecular crosslinking. Conse-
quently, in vitro studies on colon carcinoma cell lines showed that the enzymatic activity 
of dianthin and the targeting ability of EGF were preserved. The number of functionalized 
particles required to elicit the toxic effect was tremendously reduced in a combinatorial 
Figure 8. (A) T1 and (B) T2 relaxivity measurements of SPION@APTES and the SPION-DiaEGF+ I -SO1861 mixture.
Values of relaxivites (r1 and r2) were determined via correlation between the relaxation rates and the corresponding iron
concentrations from the slope of the resulting linear regression curve.
4. Conclusions
Thi stu y presented the potential impact of glycosylated triterpenoids on SPION-
based targe ed tumor the apies. For this purpose, SPIONs were synthesized and selectively
fu ctionalized with Dia or DiaEGF, by the u e of strain-promoted copper-free click chem-
istry. Ext nsive haracterization of the as-synth sized and -functionalized particle systems
showed that the function lization process resulte in defined SPION-based anti-tumor
cell systems without unspecific interparticle or intermolecular crosslinking. Consequently,
in vitro studies on c lon carcinoma cell lines showed that the enzy atic acti it of dianthin
and the targeting ability of E F ere preserved. The nu ber of functionalized particles re-
quired to elicit the toxic effect was tremendously reduced in a combinatorial approach with
the addition of free SO1861 by an enhancement factor of 21000 and 33000 for dianthin and
dianthin-EGF-modified SPIONs, respectively. Finally, SO1861 was also coordinated on the
SPION surface in order to unify the disparate pharmacokinetics of the single components,
dianthin-EGF and SO1861. In this way, cytotoxicity was enhanced 270 and 1800 times after
applying SPION-Dia or SPION-DiaEGF combined with SPION-SO1861, thus resulting in a
substantial widening of the therapeutic window in cell culture. Accordingly, the efficacy
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of the nanoparticulate formulations was substantially improved, which facilitates the ac-
ceptance of this drug delivery system from a clinical perspective. Furthermore, relaxivity
measurements of the combined particle mixture of SPION-DiaEGF and SPION-SO1861
have shown that the utilized particles could potentially serve for theranostic approaches.
This study thereby offers new opportunities for the design of novel nanoparticle-based
anti-tumor agents by reducing the effective drug concentration and thus possible side
effects of tumor therapies.
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nm, Figure S8: Cytotoxicity studies of Dia and DiaEGF conjugates on EGFR-overexpressing HCT-116
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>1 mM Fe3+.
Author Contributions: Conceptualization, A.Z., H.F. and G.G.; methodology, A.Z. and M.A.-B.;
investigation and experiments, A.Z., D.A.S., and A.T.; validation, V.M., M.A.-B., and H.F.; formal
analysis, V.M. and A.T.; resources, G.G. and H.F.; writing—original draft preparation, A.Z.; writing—
review and editing, M.A.-B., G.G., and H.F.; supervision, M.A.-B. and D.A.S.; project administration,
G.G. and H.F. All authors have read and agreed to the published version of the manuscript.
Funding: This research received no external funding.
Data Availability Statement: Data are available upon request.
Acknowledgments: The authors thank Daniela Scholz from the Institute for Particle Technology for
performing the TGA measurements.
Conflicts of Interest: The authors declare no conflict of interest.
References
1. Ferlay, J.; Colombet, M.; Soerjomataram, I.; Mathers, C.; Parkin, D.M.; Piñeros, M.; Znaor, A.; Bray, F. Estimating the global cancer
incidence and mortality in 2018: GLOBOCAN sources and methods. Int. J. Cancer 2019, 144, 1941–1953. [CrossRef]
2. Pastan, I.; Hassan, R.; Fitzgerald, D.J.; Kreitman, R.J. Immunotoxin therapy of cancer. Nat. Rev. Cancer 2006, 6, 559–565. [CrossRef]
3. Koo, O.M.; Rubinstein, I.; Onyuksel, H. Role of nanotechnology in targeted drug delivery and imaging: A concise review.
Nanomedicine 2005, 1, 193–212. [CrossRef]
4. Arteaga, C.L. Epidermal growth factor receptor dependence in human tumors: More than just expression? Oncologist 2002, 7
(Suppl. 4), 31–39. [CrossRef]
5. Salomon, D.S.; Brandt, R.; Ciardiello, F.; Normanno, N. Epidermal growth factor-related peptides and their receptors in human
malignancies. Crit. Rev. Oncol. Hematol. 1995, 19, 183–232. [CrossRef] [PubMed]
6. Rocha-Lima, C.M.; Soares, H.P.; Raez, L.E.; Singal, R. EGFR targeting of solid tumors. Cancer Control 2007, 14, 295–304. [CrossRef]
7. Simon, N.; FitzGerald, D. Immunotoxin Therapies for the Treatment of Epidermal Growth Factor Receptor-Dependent Cancers.
Toxins 2016, 8, 137. [CrossRef] [PubMed]
8. Wykosky, J.; Fenton, T.; Furnari, F.; Cavenee, W.K. Therapeutic targeting of epidermal growth factor receptor in human cancer:
Successes and limitations. Chin. J. Cancer 2011, 30, 5–12. [CrossRef] [PubMed]
9. Canton, I.; Battaglia, G. Endocytosis at the nanoscale. Chem. Soc. Rev. 2012, 41, 2718–2739. [CrossRef]
10. Puri, M.; Kaur, I.; Perugini, M.A.; Gupta, R.C. Ribosome-inactivating proteins: Current status and biomedical applications. Drug
Discov. Today 2012, 17, 774–783. [CrossRef]
11. Smith, S.A.; Selby, L.I.; Johnston, A.P.R.; Such, G.K. The Endosomal Escape of Nanoparticles: Toward More Efficient Cellular
Delivery. Bioconjugate Chem. 2019, 30, 263–272. [CrossRef]
12. Bhargava, C.; Dürkop, H.; Zhao, X.; Weng, A.; Melzig, M.F.; Fuchs, H. Targeted dianthin is a powerful toxin to treat pancreatic
carcinoma when applied in combination with the glycosylated triterpene SO1861. Mol. Oncol. 2017, 11, 1527–1543. [CrossRef]
Nanomaterials 2021, 11, 1057 15 of 16
13. Fuchs, H.; Niesler, N.; Trautner, A.; Sama, S.; Jerz, G.; Panjideh, H.; Weng, A. Glycosylated Triterpenoids as Endosomal Escape
Enhancers in Targeted Tumor Therapies. Biomedicines 2017, 5, 14. [CrossRef]
14. Baluna, R.; Vitetta, E.S. Vascular leak syndrome: A side effect of immunotherapy. Immunopharmacology 1997, 37, 117–132.
[CrossRef]
15. Kuus-Reichel, K.; Grauer, L.S.; Karavodin, L.M.; Knott, C.; Krusemeier, M.; Kay, N.E. Will immunogenicity limit the use, efficacy,
and future development of therapeutic monoclonal antibodies? Clin Diagn Lab Immunol 1994, 1, 365–372. [CrossRef] [PubMed]
16. Selbo, P.K.; Bostad, M.; Olsen, C.E.; Edwards, V.T.; Høgset, A.; Weyergang, A.; Berg, K. Photochemical internalisation, a minimally
invasive strategy for light-controlled endosomal escape of cancer stem cell-targeting therapeutics. Photochem. Photobiol. Sci. 2015,
14, 1433–1450. [CrossRef] [PubMed]
17. Zhang, D.; Wang, J.; Xu, D. Cell-penetrating peptides as noninvasive transmembrane vectors for the development of novel
multifunctional drug-delivery systems. J. Control. Release 2016, 229, 130–139. [CrossRef]
18. Fuchs, H.; Bachran, C.; Flavell, D. Diving through Membranes: Molecular Cunning to Enforce the Endosomal Escape of
Antibody-Targeted Anti-Tumor Toxins. Antibodies 2013, 2, 209–235. [CrossRef]
19. Ag Seleci, D.; Seleci, M.; Stahl, F.; Scheper, T. Tumor homing and penetrating peptide-conjugated niosomes as multi-drug carriers
for tumor-targeted drug delivery. RSC Adv. 2017, 7, 33378–33384. [CrossRef]
20. Bachran, C.; Bachran, S.; Sutherland, M.; Bachran, D.; Fuchs, H. Preclinical Studies of Saponins for Tumor Therapy. In Recent
Advances in Medicinal Chemistry; Atta-ur-Rahman, Choudhary, M.I., Perry, G., Eds.; Bentham Science Publishers: Sharjah, United
Arab Emirates, 2014; pp. 272–302.
21. Fuchs, H.; Bachran, D.; Panjideh, H.; Schellmann, N.; Weng, A.; Melzig, M.F.; Sutherland, M.; Bachran, C. Saponins as tool for
improved targeted tumor therapies. Curr. Drug Targets 2009, 10, 140–151. [CrossRef] [PubMed]
22. Bachran, C.; Bachran, S.; Sutherland, M.; Bachran, D.; Fuchs, H. Saponins in tumor therapy. Mini-Rev. Med. Chem. 2008, 8, 575–584.
[CrossRef] [PubMed]
23. Gilabert-Oriol, R.; Mergel, K.; Thakur, M.; Mallinckrodt, B.; von Melzig, M.F.; Fuchs, H.; Weng, A. Real-time analysis of membrane
permeabilizing effects of oleanane saponins. Bioorg. Med. Chem. 2013, 21, 2387–2395. [CrossRef]
24. Mallinckrodt, B.; von Thakur, M.; Weng, A.; Gilabert-Oriol, R.; Dürkop, H.; Brenner, W.; Lukas, M.; Beindorff, N.; Melzig,
M.F.; Fuchs, H. Dianthin-EGF is an effective tumor targeted toxin in combination with saponins in a xenograft model for colon
carcinoma. Future Oncol. 2014, 10, 2161–2175. [CrossRef] [PubMed]
25. Weng, A.; Thakur, M.; Beceren-Braun, F.; Bachran, D.; Bachran, C.; Riese, S.B.; Jenett-Siems, K.; Gilabert-Oriol, R.; Melzig, M.F.;
Fuchs, H. The toxin component of targeted anti-tumor toxins determines their efficacy increase by saponins. Mol. Oncol. 2012, 6,
323–332. [CrossRef]
26. Bachran, C.; Weng, A.; Bachran, D.; Riese, S.B.; Schellmann, N.; Melzig, M.F.; Fuchs, H. The distribution of saponins in vivo
affects their synergy with chimeric toxins against tumours expressing human epidermal growth factor receptors in mice. Br. J.
Pharmacol. 2010, 159, 345–352. [CrossRef]
27. Choi, H.S.; Liu, W.; Liu, F.; Nasr, K.; Misra, P.; Bawendi, M.G.; Frangioni, J.V. Design considerations for tumour-targeted
nanoparticles. Nat. Nanotechnol. 2010, 5, 42–47. [CrossRef]
28. Ling, D.; Hyeon, T. Chemical design of biocompatible iron oxide nanoparticles for medical applications. Small 2013, 9, 1450–1466.
[CrossRef]
29. Bourrinet, P.; Bengele, H.H.; Bonnemain, B.; Dencausse, A.; Idee, J.-M.; Jacobs, P.M.; Lewis, J.M. Preclinical safety and pharma-
cokinetic profile of ferumoxtran-10, an ultrasmall superparamagnetic iron oxide magnetic resonance contrast agent. Investig.
Radiol. 2006, 41, 313–324. [CrossRef] [PubMed]
30. Patsula, V.; Moskvin, M.; Dutz, S.; Horák, D. Size-dependent magnetic properties of iron oxide nanoparticles. J. Phys. Chem. Solids
2016, 88, 24–30. [CrossRef]
31. Ma, D. Enhancing endosomal escape for nanoparticle mediated siRNA delivery. Nanoscale 2014, 6, 6415–6425. [CrossRef]
[PubMed]
32. Maurer, V.; Frank, C.; Porsiel, J.C.; Zellmer, S.; Garnweitner, G.; Stosch, R. Step-by-step monitoring of a magnetic and SERS-active
immunosensor assembly for purification and detection of tau protein. J. Biophotonics 2020, 13, e201960090. [CrossRef] [PubMed]
33. Asadian-Birjand, M.; Biglione, C.; Bergueiro, J.; Cappelletti, A.; Rahane, C.; Chate, G.; Khandare, J.; Klemke, B.; Strumia, M.C.;
Calderón, M. Transferrin Decorated Thermoresponsive Nanogels as Magnetic Trap Devices for Circulating Tumor Cells. Macromol.
Rapid Commun. 2016, 37, 439–445. [CrossRef]
34. Gilabert-Oriol, R.; Thakur, M.; Weise, C.; Dernedde, J.; Mallinckrodt, B.; von Fuchs, H.; Weng, A. Small structural differences
of targeted anti-tumor toxins result in strong variation of protein expression. Protein Expr. Purif. 2013, 91, 54–60. [CrossRef]
[PubMed]
35. Gilabert-Oriol, R.; Weng, A.; Trautner, A.; Weise, C.; Schmid, D.; Bhargava, C.; Niesler, N.; Wookey, P.J.; Fuchs, H.; Thakur,
M. Combinatorial approach to increase efficacy of Cetuximab, Panitumumab and Trastuzumab by dianthin conjugation and
co-application of SO1861. Biochem. Pharmacol. 2015, 97, 247–255. [CrossRef] [PubMed]
36. Gilabert-Oriol, R.; Thakur, M.; Haussmann, K.; Niesler, N.; Bhargava, C.; Görick, C.; Fuchs, H.; Weng, A. Saponins from Saponaria
officinalis L. Augment the Efficacy of a Rituximab-Immunotoxin. Planta Med. 2016, 82, 1525–1531. [CrossRef] [PubMed]
Nanomaterials 2021, 11, 1057 16 of 16
37. Balin-Gauthier, D.; Delord, J.-P.; Rochaix, P.; Mallard, V.; Thomas, F.; Hennebelle, I.; Bugat, R.; Canal, P.; Allal, C. In vivo and
in vitro antitumor activity of oxaliplatin in combination with cetuximab in human colorectal tumor cell lines expressing different
level of EGFR. Cancer Chemother. Pharmacol. 2006, 57, 709–718. [CrossRef] [PubMed]
38. Anido, J.; Matar, P.; Albanell, J.; Guzmán, M.; Rojo, F.; Arribas, J.; Averbuch, S.; Baselga, J. ZD1839, a specific epidermal growth
factor receptor (EGFR) tyrosine kinase inhibitor, induces the formation of inactive EGFR/HER2 and EGFR/HER3 heterodimers
and prevents heregulin signaling in HER2-overexpressing breast cancer cells. Clin. Cancer Res. 2003, 9, 1274–1283. [PubMed]
39. Zarinwall, A.; Waniek, T.; Saadat, R.; Braun, U.; Sturm, H.; Garnweitner, G. Comprehensive Characterization of APTES Surface
Modifications of Hydrous Boehmite Nanoparticles. Langmuir 2020. [CrossRef]
40. Fuchs, H. Dianthin and Its Potential in Targeted Tumor Therapies. Toxins 2019, 11, 592. [CrossRef]
41. Weng, A. A novel adenine-releasing assay for ribosome-inactivating proteins. J. Chromatogr. B 2018, 1072, 300–304. [CrossRef]
42. Masthoff, I.-C.; Kraken, M.; Mauch, D.; Menzel, D.; Munevar, J.A.; Baggio Saitovitch, E.; Litterst, F.J.; Garnweitner, G. Study of
the growth process of magnetic nanoparticles obtained via the non-aqueous sol–gel method. J. Mater. Sci. 2014, 49, 4705–4714.
[CrossRef]
43. Park, C.; Vo, C.L.-N.; Kang, T.; Oh, E.; Lee, B.-J. New method and characterization of self-assembled gelatin-oleic nanoparticles
using a desolvation method via carbodiimide/N-hydroxysuccinimide (EDC/NHS) reaction. Eur. J. Pharm. Biopharm. 2015, 89,
365–373. [CrossRef]
44. Vranic, S.; Gatalica, Z.; Wang, Z.-Y. Update on the molecular profile of the MDA-MB-453 cell line as a model for apocrine breast
carcinoma studies. Oncol. Lett. 2011, 2, 1131–1137. [CrossRef]
45. Bachran, D.; Schneider, S.; Bachran, C.; Urban, R.; Weng, A.; Melzig, M.F.; Hoffmann, C.; Kaufmann, A.M.; Fuchs, H. Epidermal
growth factor receptor expression affects the efficacy of the combined application of saponin and a targeted toxin on human
cervical carcinoma cells. Int. J. Cancer 2010, 127, 1453–1461. [CrossRef] [PubMed]
46. Wayne, A.S.; Fitzgerald, D.J.; Kreitman, R.J.; Pastan, I. Immunotoxins for leukemia. Blood 2014, 123, 2470–2477. [CrossRef]
47. Rosen, J.E.; Chan, L.; Shieh, D.-B.; Gu, F.X. Iron oxide nanoparticles for targeted cancer imaging and diagnostics. Nanomedicine
2012, 8, 275–290. [CrossRef] [PubMed]
48. Huang, J.; Zhong, X.; Wang, L.; Yang, L.; Mao, H. Improving the magnetic resonance imaging contrast and detection methods
with engineered magnetic nanoparticles. Theranostics 2012, 2, 86–102. [CrossRef] [PubMed]
49. Rohrer, M.; Bauer, H.; Mintorovitch, J.; Requardt, M.; Weinmann, H.-J. Comparison of magnetic properties of MRI contrast media
solutions at different magnetic field strengths. Investig. Radiol. 2005, 40, 715–724. [CrossRef]
